Freedom of Information Request: Our Reference CTMUHB_02_26

You asked:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Bimekizumab**
- **Brodalumab**
- **Certolizumab**
- **Deucravacitinib**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Guselkumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Ustekinumab - Stelara**
- **Ustekinumab Biosimilar**
- **Omalizumab**
- **Spesolimab**

Please find below a table populated with the information Medicines Management is able to provide at present in relation to question 1. The period the data covers refers to 1st October 2025 to 31st December 25, the latest 3 months available as requested.

Medicine	Number of Patients
Adalimumab – Humira	**
Adalimumab Biosimilar	83
Apremilast	16
Bimekizumab	17
Brodalumab	**
Certolizumab	6
Deucravacitinib	23
Dimethyl fumarate	0
Etanercept – Enbrel	0
Etanercept Biosimilar	**
Guselkumab	60

Infliximab – Remicade	**
Infliximab Biosimilar	**
Ixekizumab	17
Risankizumab	64
Secukinumab	10
Tildrakizumab	15
Ustekinumab – Stelara	**
Ustekinumab Biosimilar	47
Omalizumab	55
Spesolimab	**

Please note - where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR**.** We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Bimekizumab**
- **Certolizumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Secukinumab**
- **Ustekinumab - Stelara**
- **Ustekinumab Biosimilar**

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.